MARY HALLORAN-RUHLE: Open Payments
NPI 1730236142 · TROY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,356 in 223 payments from 14 companies in 2025. Trend: 2023 $4,463 · 2024 $4,991 · 2025 $4,356
Food & beverage: $4,356
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 48 | $872 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 31 | $705 |
| Alkermes, Inc. | 19 | $596 |
| Otsuka America Pharmaceutical, Inc. | 35 | $566 |
| E.R. Squibb & Sons, L.L.C. | 27 | $448 |
| Teva Pharmaceuticals USA, Inc. | 25 | $358 |
| Axsome Therapeutics, Inc. | 10 | $232 |
| Neurocrine BioSciences, Inc. | 11 | $217 |
| ABBVIE INC. | 7 | $157 |
| Vanda Pharmaceuticals Inc. | 4 | $65 |
Products named: CAPLYTA, ARISTADA, INVEGA SUSTENNA, COBENFY, SPRAVATO, REXULTI, AUSTEDO XR, Auvelity.
Industry payments across NY — which companies pay providers there.
